anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Liver cancer in adult men is the fifth most frequently diagnosed cancer worldwide, and is the second leading cause of cancer-related death in the world. In adult women, it is the seventh most commonly diagnosed cancer and the sixth leading cause of cancer death. The two main types of liver cancer are hepatocellular carcinoma (HCC) and mass-forming cholangiocarcinoma (MFCCC). The annual overall incidence is approximately 70 and 2 per 100,000 inhabitants for HCC and MFCCC respectively.

To date, liver surgery is the treatment of choice for those patients with resectable disease. For some other patients, with specific tumor features, liver transplantation may be applied with good results. However, still today the proportion of resectable or transplantable patients is limited due to a large proportion of patients presenting with advances disease. For these patients, the treatment consists of systemic chemotherapy, which unfortunately is associated with median survival of 12 months. The choice of the appropriate treatment scheme adheres to the standard guidelines based on the results of clinical trials. Of note, in case of HCC and MFCCC very few international approved therapeutic guidelines are available. In particular, there is no agreement among specialists about the use of chemotherapy as adjuvant treatment after hepatic resection for HCC or MFCCC. In other words, in the actual clinical practice a patient operated for HCC or MFCCC generally does not receive postoperative adjuvant chemotherapy.

Another important aspect of the postoperative adjuvant therapy is the possibility to enhance the recovery after the operation. Indeed, the possibility to accelerate the functional recovery in a patient who receives a major cancer operation is of paramount importance. In this sense, having a product that might help the patients' recovery should be one of the priorities of the medical and pharmaceutical industry. To our knowledge, there are no previous studies that investigated such an important aspect.

Synchro Levels consists of a supplemental nutritional therapy that has been present on the market for more than 15 years. Some studies reported its safety and efficacy in patients with different advanced solid tumors showing an unexpected rate of partial response. However, very few data are available on its role in improving the patients' performance status and the quality of life. This research project aims to test the role of Synchro Levels in enhancing the functional recovery of patients submitted to hepatectomy for HCC or MFCCC.
PURPOSE: A pharmaceutical composition and health functional food containing thienylbutyl isothiocyanate are provided to inhibit adipocyte differentiation. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity and lipid-related metabolic disorders contains 0.1-50 wt% of thienylbutyl isothiocyanate as an active ingredient. The composition is administered in 0.01-500 mg/kg. The composition is manufactured in the form of powder, granules, tablets, capsules, suspension, emulsion, syrup, oral administration, external use formulation, suppository, or sterilized injection solution. A health functional for preventing and relieving obesity and lipid-related metabolic diseases contains the thienyl butyl isothiocyanate as an active ingredient. The health functional food is manufactured in the form of capsules, tablets, granules, powder, or beverage.
The hypothesis is that buspirone is a safe, effective drug to reduce the occurrence of recurrent central apnea and irregular breathing found in the setting of heart failure. A secondary hypothesis is that its effect will be similar to that or acetazolamide. Study Design: A one-dose double-blind crossover study of buspirone vs. placebo vs. acetazolamide will be performed to determine if active drug alters the number and/or severity of recurrent central apneas and hypopneas (AHI) in patients with heart failure. AHI is the primary outcome variable. In the initial phase of this study, we will recruit 18-20 patients to obtain \~15 complete studies, using the assumption of a \~20% drop-out, to reach a pre-set significance level of a 30% reduction in AHI in the drug groups with a power of 0.90 and a p=0.05 by post-hoc testing. Power estimates were calculated using the means and SDs derived from the population reported the study of acetazolamide by Javaheri et al (2006). A 30% reduction in AHI would be meaningful. A 15% dropout rate was present in the study by Javaheri et al (2006), but as our study is a three-way comparison, we chose a slightly higher rate. The reasons stated in these articles for a drop out included: viral illness, GI upset (on placebo or on theophyllin), tired of the sleep studies, and desire to terminate without cause. Statistical Analyses. Analysis of variance for repeated measures using Sidak's correction will be used to compare placebo, buspirone, and acetazolamide studies. For variables that are not normally distributed, Dunn's nonparametric test for multiple comparisons will be used. p \> 0.05 will be considered significant. Mean values and SDs will be reported. This single dose, one night study is called Buspirone as a Potential Treatment for Recurrent Sleep Apnea I.

The randomization will be in a block design, and the analysis will take into account the blocked design. We will recruit 30 patients to obtain \~27 complete studies, using the assumption of a \~25% drop-out, to reach a pre-set significance level of a 50% reduction in AHI in the drug groups with a power of 0.90 and a p=0.05 by post-hoc testing (see Table C below). Power estimates were calculated using the means and SDs derived from the population reported the study of a one week trial of acetazolamide by Javaheri, values similar to those in the drug trial for theophyllin. Our reasoning is that a 50% reduction in AHI would be most meaningful. Our drop-out rate in the one-night study is estimated at \~25%.

Exclusion criteria of use of selective serotonin reuptake inhibitors (SSRIs) or antidepressants, while necessary because one of the drugs was buspirone, were too stringent for completion of this study in the VA setting. Of \~1000 patient charts screens, 8 were eventually entered into the trial, so that power criteria were not met. Records are being utilized to probe for hidden features in the PSG for use in future drug trials.
PURPOSE:To obtain a hair rearing agent obtained by blending polygoni multiflori radix and ginseng used as main ingredients with at least Rehmanniae Radix and Angelicae Radix, free from side effects, capable of rearing hair as well as changing white hair to black hair and readily taking. CONSTITUTION:Powder of polygoni multifloriflorum radix obtained by steaming and drying the root of Polygonum multiflorum Thumb, and powder of root of Panax ginseng are blended at amounts of each 30-40wt.% and 40-50wt.% based on the total weight and further blended with 0.01-0.05wt.% Rehmanniae Radix powder and 0.01-0.05wt.% Angelicae Radix powder. The blend is solidified and granulated or liquefied using an usual diluting agent or singly granulated to provide the aimed product. Hair can be blackened and reared by the polygoni multiflori radix, because the radix promotes blood circulation together with other ingredient and supplies the blood. The Rehmanniae Radix has effects to antasthenic and blood supply and promotes rearing of hair as a result. The agent has effects also to nourishment and antasthenic, improvement of infirmity and feeding of nutrition.
Erectile dysfunction, the inability to attain or sustain a penile erection sufficient to permit satisfactory sexual intercourse, affects an estimated ten to 30 million men in the United States. Erectile dysfunction can be caused by many organic abnormalities, including diabetes mellitus, hypertension, vascular disease, neurogenic disorders, and other chronic diseases. Erectile dysfunction can be effectively treated with a variety of methods, including the implantation of an inflatable penile prosthesis. A multi-center trial is to be conducted to assess the AMS IPP 2002 Inflatable Penile Prosthesis including handling during IPP implantation procedures and short-term follow-up experience of subjects. The study will collect pre-operative information comparing the pump operation using scrotal models of the current pump with the study pump, and baseline erectile function history. Surgical data will be collected to assess device design and procedure enhancements. Patient and physician assessment of study device function, ease of use, ease of training/learning, and adverse events will be gathered post-operatively.
The iFightDepression-Survive (iFD-S) program is a cognitive-behavioral, internet-based self-management tool, developed by the European Alliance Against Depression (EAAD). The iFD is intended to address mild-to-moderate depressive symptoms. The iFD tool is structured in seven core modules focused on: behavioral activation, cognitive restructuring, sleep regulation, mood monitoring, and healthy lifestyle habits. The content of each module is intended to be followed over 1 week and consists of written information, tasks to do over the week and worksheets. All of these aims to consolidate learning and promote self-monitoring. For this study, an additional module (iFD-S) will be developed. To that end, the expertise of a panel of mental health experts in suicide and cognitive-behavioral interventions will be asked. The iFD-S also provides telephone guidance (2h per participant) during the use of the program.
BACKGROUND: Refractory chronic cough (RCC) and unexplained chronic cough (UCC) adversely affect patients' quality of life (QoL). This multicenter, non-interventional study evaluates the relationship between cough severity and QoL and other patient-reported outcomes (PROs) in Spanish outpatients.
METHODS: RCC/UCC patients self-administered a printed survey comprising the cough-severity visual analog scale (VAS), adapted Cough Severity Diary (CSD), and Leicester Cough Questionnaire (LCQ), plus purpose-designed items regarding the physical and everyday-life impact of cough. Patients were stratified into VAS score tertiles. The impact of cough on QoL and other PROs in each tertile, and relationships between LCQ scores and the tertiles, were assessed.
RESULTS: The VAS was completed by 189 patients, and VAS score tertiles were identified as 0-50, 60-70, and 80-100 mm. The only between-tertile difference in demographic or cough characteristics was cough duration. VAS score tertiles were linearly associated with mean LCQ domain and total scores, as well as the proportion of patients with the highest scores on all adapted CSD items, and almost all physical and everyday-life impact items. In multiple linear-regression models, an increase of one tertile in the VAS score was associated with a decrease of 2.23 points in the LCQ total score, indicating poorer cough-related QoL.
CONCLUSION: As self-assessed in patients with RCC/UCC, cough-severity VAS scores were strongly associated with the impact of cough on QoL and everyday life. Patients with VAS scores of 60-100 mm reported the greatest impact and thus may benefit the most from targeted cough therapies.
PURPOSE: A composition containing Allium fistulosum L. extract for preventing and treating lipis-associated cardiovascular diseases or obesity is provided to suppress body fat and lipid synthesis. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity contains Allium fistulosum L. extract as an active ingredient. The extract is prepared using water, low alcohol of C1-C4, or mixture thereof. A method for preparing the extract comprises: a step of adding solvent to the dry Allium fistulosum L. and extracting; a step of filtering the extract; and a step of decompressing the extract. The low alcohol is ethanol or methanol. A health food for preventing and treating obesity contains the extract as an active ingredient. A pharmaceutical composition for preventing and treating lipid-associated cardiovascular diseases contains the extract as an active ingredient.
Carbapenem-resistant Klebsiella pneumoniae (CRKP) infections are a major public health problem, requiring the use of last-resort antibiotics such as colistin. However, there is concern regarding the emergence of isolates resistant to this agent. The report describes two patients with urinary tract infection (UTI) and ventilator-associated pneumonia (VAP) infection caused by CRKP strains. The first case was a 23-year-old male with UTI caused by a strain of ST16 co-harboring blaCTX-M, blaTEM, blaSHV, blaNDM, blaOXA-48-like genes. The second case was a 39-year-old woman with VAP due to hypervirulent ST337-K2 co-harboring blaSHV, blaNDM, blaOXA-48-like, iucA, rmpA2 and rmpA. The patients' general condition improved after combination therapy with colistin (plus meropenem and rifampin, respectively) and both of them recovered and were discharged from the hospital. This study highlights the necessary prevention and control steps to prevent the further spread of CRKP strains should be a priority in our hospital.
PROBLEM TO BE SOLVED: To obtain a lamellar structure, having excellent humectant performances excellent in water holding ability of a horny layer and useful as an active ingredient of a cosmetic or a therapeutic agent for dermatosis by including a complex of a sucrose ester of a fatty acid with a sterol or its derivative as a constituent ingredient therein. SOLUTION: This lamellar structure is obtained by uniformly dissolving a sterol (preferably cholesterol, etc.) or its derivative (an ester, etc., of the sterol with a fatty acid, e.g. dicholesteryl N-lauroyl-L-glutamate) in an amount of preferably 10-100wt.% based on a sucrose ester of the fatty acid (which is an ester of sucrose with a 10-24C fatty acid, e.g. sucrose monopalmitate, etc.) in an organic solvent, removing the organic solvent from the resultant solution in the organic solvent, simultaneously depositing the sucrose ester of the fatty acid and cholesterol or its derivative, providing a complex of the sucrose ester of the fatty acid with the sterol or its derivative and further stirring and dispersing a mixture of the complex with water. The resultant lamellar structure contains the complex as a constituent ingredient.
BACKGROUND AND AIMS: To explore the relationship between body mass index (BMI), chinese visceral adiposity index (CVAI) and the risk of metabolic dysfunction-associated steatotic liver disease (MASLD) in populations with different body types defined by BMI.
METHODS AND RESULTS: 24 191 participants from the Jinchang cohort were involved in the prospective cohort study with a 2.3-year follow-up. Information from epidemiological investigations, comprehensive health examinations and biochemical examinations was collected. MASLD was assessed by abdominal ultrasonography. BMI and CVAI were calculated using recognized formulas. Cox regressions, Restricted cubic spline (RCS) and Receiver operating characteristic (ROC) analysis were performed. The risk of MASLD increased with the increase in BMI and CVAI (Ptrend <0.001), and there was a nonlinear dose-response relationship. In the total population, BMI and CVAI increased the risk of MASLD with adjusted HR (95%CI) of 1.097 (1.091-1.104) and 1.024 (1.023-1.026), respectively. The results were similar in the lean and overweight/obese groups. There was also a nonlinear relationship between CVAI and MASLD (Pnon-linearity<0.001), no matter in which group. The area under the curve of CVAI was significantly higher than that of BMI in females with different body types, and the areas in the whole females were 0.802 (95%CI: 0.787-0.818) and 0.764 (95%CI: 0.747-0.780), respectively. There was no significant difference in the ability of BMI and CVAI to predict MASLD in all-sex and males, either in lean or overweight/obese groups.
CONCLUSIONS: CVAI and BMI were independently associated with the risk of MASLD regardless of body types defined by BMI, and CVAI showed better diagnostic ability for MASLD in females.
The present invention relates to a multipotent stem cell, multipotent cell populations, and an enriched multipotent cell population, each found in fetal, neonatal, pediatric, and adult biliary tree tissue and up to 72 hours post mortem (although preferentially, within 10 hours post mortem) and capable of maturing into multiple endodermal tissues that include liver, biliary and pancreatic tissues. The multipotent stem/progenitor cell and cell populations are found in peribiliary glands, and progenitors descending from them are present throughout the biliary tree including in the gallbladder. High numbers of the peribiliary glands are found in the branching locations of the biliary tree such as hilum, common hepatic duct, cystic duct, common duct, common hepato-pancreatic duct and gallbladder. Related multipotent cells, multipotent cell populations and their descendent progenitors are found throughout the biliary tree including in the gall bladder, which does not have peribiliary glands. Compositions comprising same, methods of identifying and isolating same, maintaining same in culture, expanding same in culture and differentiating or lineage restricting the same in vitro or in vivo to hepatic, biliary or pancreatic fates (e.g., as hepatocytes, cholangiocytes, and/or pancreatic islet cells) are also provided. Methods of using the multipotent cells and/or multipotent cell populations are also provided.
The utility model discloses a facial mask capable of preventing water from evaporating. A hydrophobic compact layer for preventing water from evaporating is arranged on the outer surface of a liquid carrier of the facial mask. The hydrophobic compact layer can be formed by a modified maize starch film sprayed on the outer surface of the liquid carrier of the facial mask, formed by a silica gel film, a PE (Polyurethane) film or a latex film which is wrapped on the outer surface of the liquid carrier of the facial mask or formed by other hydrophobic films. The hydrophobic compact layer is formed by the modified maize starch film sprayed on the outer surface of the liquid carrier of the facial mask or formed by the silica gel film wrapped on the outer surface of the liquid carrier of the facial mask, the hydrophobic compact layer extends downward to form a protection part, and the inner surface of the protection part is provided with a water absorption layer. As the hydrophobic compact layer is arranged on the outer surface of the carrier of the facial mask, facial mask liquid can be prevented from evaporating over fast when the facial mask is used, and the hydrophobic compact layer has a thermal insulation function when the facial mask is used in winter. The hydrophobic compact layer is favorable for skin to fully absorb the facial mask liquid, and the protection part extending downward from the hydrophobic compact layer can absorb the facial mask liquid dropping from the carrier of the facial mask, can prevent the collar from being polluted and the like.
The present invention relates to a body resistance strengthening small injection with fructus ligustri lucidi and astragalus root, and a preparation method thereof. The present invention has the medicinal formulations of the following proportion by weight: fructus ligustri lucidi accounts for 10 to 90%, and astragalus root accounts for 90 to 10%. The preparation method comprises the following technologic procedures: 1. pretreatment of medicinal materials; 2. extraction technology; in the extraction technology, effective parts of polyoses, fructus ligustri lucidi and total saponin of astragalus root are obtained; 3. preparation technology; the relevant effective parts of total saponin of astragalus root and fructus ligustri lucidi, and the effective parts of polyoses are added with proper amounts of water for injection to dissolve the effective parts; the mixture is added with an isotonic modifying agent and a preservative, and is prepared into a solution by water for injection; the solution is added with active carbon for injection, boiled and filtered; the pH value of the solution is regulated, and the solution is filtered; a finished product is obtained after packaging. The present invention has the advantages that the product is an injection, and the route of administration is injecting administration. The injection dispenses with digestive absorption of gastrointestinal tracts, and has the characteristics of outstanding curative effect and obvious effect. The present invention has a consummate and reasonable technologic route, and the injection is rich in effective components of fructus ligustri lucidi and astragalus root of which the purity are high. The sample has stable quality, which conforms to the quality requirement of cures, and is easy to transport.
Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle.The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
Collagen type XVIII (COL18) is an abundant heparan sulfate proteoglycan in vascular basement membranes. Here, we asked (i) if the loss of COL18 would result in blood-brain barrier (BBB) breakdown, pathological alterations of small arteries and capillaries and neuroinflammation as found in cerebral small vessel disease (CSVD) and (ii) if such changes may be associated with remodeling of synapses and neural extracellular matrix (ECM). We found that 5-month-old Col18a1-/- mice had elevated BBB permeability for mouse IgG in the deep gray matter, and intravascular erythrocyte accumulations were observed brain-wide in capillaries and arterioles. BBB permeability increased with age and affected cortical regions and the hippocampus in 12-month-old Col18a1-/- mice. None of the Col18a1-/- mice displayed hallmarks of advanced CSVD, such as hemorrhages, and did not show perivascular space enlargement. Col18a1 deficiency-induced BBB leakage was accompanied by activation of microglia and astrocytes, a loss of aggrecan in the ECM of perineuronal nets associated with fast-spiking inhibitory interneurons and accumulation of the perisynaptic ECM proteoglycan brevican and the microglial complement protein C1q at excitatory synapses. As the pathway underlying these regulations, we found increased signaling through the TGF-ß1/Smad3/TIMP-3 cascade. We verified the pivotal role of COL18 for small vessel wall structure in CSVD by demonstrating the protein's involvement in vascular remodeling in autopsy brains from patients with cerebral hypertensive arteriopathy. Our study highlights an association between the alterations of perivascular ECM, extracellular proteolysis, and perineuronal/perisynaptic ECM, as a possible substrate of synaptic and cognitive alterations in CSVD.
Described herein is a method of making modified paramagnetic nanoparticles with improved therapeutic loading efficiency and enhanced circulation properties. The method compiises coating a paramagnetic nanoparticle (PMNP) with a hydrophobic coating comprising lipophilic drug and a polymer. Also described herein is a PMNP, and a composition comprising PMNP. In certain embodiment, the PMNP have improved permeability through the blood brain barrier. Also described herein is a method of using the PMNP for the treatment of diseases. In certain embodiments, the method of treatment is a combination therapy. Described herein are imaging of therapeutic delivery of PMNP and diagnostic methods using the PMNP. Also described herein is a diagnostic kit that comprises the PMNP.